Search
Enlivex Therapeutics Ltd
ENLVAdd to Watchlist
0.277USD
-0.029-9.48%
Close 10-08 16:00（ET）
4.66MMarket Cap
0.01P/E TTM
Pre-market 07:42 (ET)0.254USD-0.023-8.30%
Pre-market 07:42 (ET)Enlivex Therapeutics Ltd (ENLV) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Enlivex Therapeutics Ltd in the past month.
Buy
0 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
80.000USD+20555.82%
ENLV Analyst Recommendation Trends
In the current month, ENLV has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ENLV average Analyst price target in the last month is 80.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
2
2
2
2
2
ENLV Analyst Rating for Peer Comparison
Updated: Oct 8, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Tempus AI Inc
TEM
4
7
11
0
1
23
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
Revolution Medicines Inc
RVMD
8
14
1
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
IQVIA Holdings Inc
IQV
8
11
3
0
0
22
Financial Forecasting
Based on analysts' estimates, ENLV EPS is projected to reach -0.280 in FY2026Q3, following reported EPS of 114.360 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q3
FY2025Q4
FY2026Q2
FY2026Q1
FY2026Q3
FY2026Q4
Forecast
--
-0.45
-0.31
-0.31
-0.28
-0.26
Actual
-0.09
167.84
114.36
--
--
--
Surprise
--
+37398.50%
+36990.18%
--
--
--
FAQs
What is Enlivex Therapeutics Ltd's price target?
Analysts forecast that Enlivex Therapeutics Ltd's price target is USD 80.00, with the highest forecast at USD 80.00 and the lowest forecast at USD 80.00.
How have Enlivex Therapeutics LtdENLV's recent earnings per share performed?
The market expectation was USD 114.36, while Enlivex Therapeutics LtdENLV's earnings per share (EPS) for the previous quarter was USD 167.84. EPS for the next quarter is expected at USD -0.28.
What is the analyst rating for Enlivex Therapeutics Ltd?
Based on the ratings of Enlivex Therapeutics Ltd's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.